RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Khosrow Kashfi to Anti-Inflammatory Agents, Non-Steroidal

This is a "connection" page, showing publications Khosrow Kashfi has written about Anti-Inflammatory Agents, Non-Steroidal.
  1. Kolawole OR, Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. Int J Mol Sci. 2022 Jan 27; 23(3).
    View in: PubMed
    Score: 0.674
  2. Kodela R, Chattopadhyay M, Vel?zquez-Mart?nez CA, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol. 2015 Dec 15; 98(4):564-72.
    View in: PubMed
    Score: 0.434
  3. Kashfi K, Chattopadhyay M, Kodela R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 2015 Dec; 6:287-296.
    View in: PubMed
    Score: 0.431
  4. Nath N, Liu X, Jacobs L, Kashfi K. Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets ?-catenin. Drug Des Devel Ther. 2013; 7:389-96.
    View in: PubMed
    Score: 0.368
  5. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 2012 Mar 15; 83(6):715-22.
    View in: PubMed
    Score: 0.335
  6. Chattopadhyay M, Velazquez CA, Pruski A, Nia KV, Abdellatif KR, Keefer LK, Kashfi K. Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs. J Pharmacol Exp Ther. 2010 Nov; 335(2):443-50.
    View in: PubMed
    Score: 0.304
  7. Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. NO-releasing NSAIDs suppress NF-?B signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 2010 Dec 08; 298(2):204-11.
    View in: PubMed
    Score: 0.304
  8. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 2005 Oct 01; 70(7):969-86.
    View in: PubMed
    Score: 0.217
  9. Nath N, Labaze G, Rigas B, Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochem Biophys Res Commun. 2005 Jan 07; 326(1):93-9.
    View in: PubMed
    Score: 0.207
  10. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med. 2004 Jul; 10(7):324-30.
    View in: PubMed
    Score: 0.199
  11. Kashfi K, Rayyan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B, Ryann Y. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther. 2002 12; 303(3):1273-82.
    View in: PubMed
    Score: 0.179
  12. Kashfi K. Anti-cancer activity of new designer hydrogen sulfide-donating hybrids. Antioxid Redox Signal. 2014 Feb 10; 20(5):831-46.
    View in: PubMed
    Score: 0.093
  13. Kashfi K, Olson KR. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol. 2013 Mar 01; 85(5):689-703.
    View in: PubMed
    Score: 0.089
  14. Jain S, Tran S, El Gendy MA, Kashfi K, Jurasz P, Vel?zquez-Mart?nez CA. Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs. J Med Chem. 2012 Jan 26; 55(2):688-96.
    View in: PubMed
    Score: 0.084
  15. Kashfi K. Anti-inflammatory agents as cancer therapeutics. Adv Pharmacol. 2009; 57:31-89.
    View in: PubMed
    Score: 0.072
  16. Kashfi K, Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun. 2007 Jul 13; 358(4):1096-101.
    View in: PubMed
    Score: 0.061
  17. Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans. 2005 Aug; 33(Pt 4):701-4.
    View in: PubMed
    Score: 0.054
  18. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther. 2005 Jul; 314(1):1-8.
    View in: PubMed
    Score: 0.052
  19. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, Rigas B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol. 2004 Jun 15; 67(12):2197-205.
    View in: PubMed
    Score: 0.050
  20. Kaza CS, Kashfi K, Rigas B. Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat. 2002 Feb; 67(2):107-20.
    View in: PubMed
    Score: 0.042
  21. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun. 2004 Jan 16; 313(3):784-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support